Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Recruiting · NCT06205485 · Interventional (participants receive a specific treatment) · Lead sponsor: Canadian Cancer Trials Group
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient.
- MRI stage cT1 not eligible for transanal surgery or cT2-T3ab\*. \* T3a: \<1mm depth invasion, T3b: 1-5mm depth of invasion.
- cN0 stage based on pelvic MRI - including absence of radiographic evidence of mesorectal nodal metastasis, tumour deposits or extramural venous invasion (EMVI).
- M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis.
- Mid to low-lying tumour eligible for transanal excision in the opinion of the treating surgeon.
- Medically fit to undergo radical TME surgery as per treating surgeon's decision.
- Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish.
- Age of at least 18 years.
- No contraindications to protocol chemotherapy.
- Adequate normal organ and marrow function: ANC ≥ x 10\^9/L; platelet count ≥ 100 x 10\^9/L; bilirubin \< 1.5 UNL, excluding Gilbert's syndrome; Estimated creatinine clearance of ≥ 50ml/min
- Patient must have an ECOG performance of \<2 (or Karnofsty ≥ 60%).
- Must be accessible for treatment and follow-up
- Males and females of reproductive potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy.
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
Exclusion criteria
- Pathologic high-risk factors on diagnostic biopsy: high histologic grade (poorly differentiated), mucinous or signet ring histology.
- Patients with visible pelvic sidewall nodes on MRI.
- Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration.
- Previous pelvic radiation for any reason, including brachytherapy alone.
- Patients who have had primary lesion excised prior to enrollment. If a patient has had partial excision prior to enrollment, there must be gross residual disease endoscopically for patient to be eligible.
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Prior treatment for rectal cancer.
- Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD).
- Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy/intervention prior to enrollment.
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
- Any contra-indications to undergo MRI imaging.
- Presence of anterior lesions above or near peritoneal reflection rendering the patient ineligible for a transanal tumour excision.
- T3 tumours invading or abutting the internal sphincter.
Where it is running
60 locations listed across 28 US states.
- Cancer Center at Saint Joseph's - Phoenix, Arizona, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine, California, United States
- Los Angeles General Medical Center - Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center - Los Angeles, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange, California, United States
- Mission Hope Medical Oncology - Santa Maria - Santa Maria, California, United States
- Beebe South Coastal Health Campus - Millville, Delaware, United States
- Helen F Graham Cancer Center - Newark, Delaware, United States
- Medical Oncology Hematology Consultants PA - Newark, Delaware, United States
- Beebe Health Campus - Rehoboth Beach, Delaware, United States
- Orlando Health Cancer Institute - Orlando, Florida, United States
- Emory University Hospital Midtown - Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute - Atlanta, Georgia, United States
- Emory Saint Joseph's Hospital - Atlanta, Georgia, United States
- Rush-Copley Medical Center - Aurora, Illinois, United States
- Northwestern University - Chicago, Illinois, United States
- Carle at The Riverfront - Danville, Illinois, United States
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb, Illinois, United States
- Carle Physician Group-Effingham - Effingham, Illinois, United States
- Northwestern Medicine Cancer Center Delnor - Geneva, Illinois, United States
- Carle Physician Group-Mattoon/Charleston - Mattoon, Illinois, United States
- Carle Cancer Center - Urbana, Illinois, United States
- Northwestern Medicine Cancer Center Warrenville - Warrenville, Illinois, United States
- Northwest Cancer Center - Crown Point - Crown Point, Indiana, United States
- Northwest Oncology LLC - Dyer, Indiana, United States
- Northwest Cancer Center - Hobart - Hobart, Indiana, United States
- Saint Mary Medical Center - Hobart, Indiana, United States
- The Community Hospital - Munster, Indiana, United States
- Northwest Cancer Center - Valparaiso - Valparaiso, Indiana, United States
- Ochsner Hematology Oncology North Shore - Covington (West Region) - Covington, Louisiana, United States
- University Medical Center New Orleans - New Orleans, Louisiana, United States
- Ochsner Medical Center Jefferson - New Orleans, Louisiana, United States
- Beverly Hospital - Beverly, Massachusetts, United States
- Lahey Clinic - Burlington, Massachusetts, United States
- Addison Gilbert Hospital - Gloucester, Massachusetts, United States
- Henry Ford Cancer Institute-Downriver - Brownstown, Michigan, United States
- Henry Ford Macomb Hospital-Clinton Township - Clinton Township, Michigan, United States
- Henry Ford Medical Center-Fairlane - Dearborn, Michigan, United States
- Henry Ford Hospital - Detroit, Michigan, United States
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital - Grand Rapids, Michigan, United States
- Allegiance Health - Jackson, Michigan, United States
- West Michigan Cancer Center - Kalamazoo, Michigan, United States
- Henry Ford Medical Center-Columbus - Novi, Michigan, United States
- Henry Ford West Bloomfield Hospital - West Bloomfield, Michigan, United States
- Henry Ford Wyandotte Hospital - Wyandotte, Michigan, United States
- Sanford Joe Lueken Cancer Center - Bemidji, Minnesota, United States
- Mercy Hospital Saint Louis - St Louis, Missouri, United States
- Renown Regional Medical Center - Reno, Nevada, United States
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center - Lebanon, New Hampshire, United States
- Memorial Sloan Kettering Basking Ridge - Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth - Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen - Montvale, New Jersey, United States
- University of New Mexico Cancer Center - Albuquerque, New Mexico, United States
- Roswell Park Cancer Institute - Buffalo, New York, United States
- Memorial Sloan Kettering Commack - Commack, New York, United States
- Memorial Sloan Kettering Westchester - Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center - New York, New York, United States
- University of Rochester - Rochester, New York, United States
- Memorial Sloan Kettering Nassau - Uniondale, New York, United States
- Wilmot Cancer Institute at Webster - Webster, New York, United States
Showing 60 of 113 listed sites. See the official record for the complete list.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →